Effects of compound 21, a non-peptide angiotensin II type 2 receptor agonist, on general anesthesia-induced cerebral injury in neonatal rats

JUN YONG, LI YAN, JING WANG, HONGMEI XIAO and QINGFAN ZENG

Department of Anesthesiology, The Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, Guizhou 550014, P.R. China

Received January 19, 2018; Accepted August 22, 2018

DOI: 10.3892/mmr.2018.9602

Abstract. General anesthesia has a great impact on neurodevelopment. However, the mechanisms underlying this effect and therapeutic methods to address it remain limited. The present study aimed to investigate the effects of compound (C)21, a non-peptide angiotensin II type 2 receptor agonist, on general anesthesia-induced cerebral injury in neonatal rats. Neonatal Sprague Dawley rats (postnatal day 7) were randomly divided into three groups (n=6 per group): The control, isoflurane and C21+ isoflurane (C21) group. General anesthesia was induced through inhalation of 1.3% isoflurane. Apoptosis and synaptic structure were analyzed. The levels of peroxisome proliferator-activated receptor (PPAR-α) and Bcl-2 expression, at the mRNA and protein levels, was significantly reduced in the isoflurane group compared with the control (P<0.05). A reduction in synapse number was observed in the isoflurane group compared with the control. By contrast, nuclei shrinkage and the decrease in synaptic number was improved in the C21 group. PPAR-α and Bcl-2 expression, at the mRNA and protein levels, was significantly reduced in the isoflurane group compared with the control (P<0.05). C21 treatment reduced the decrease in PPAR-α and Bcl-2 in the cerebral cortex, hippocampus, amygdala and hypothalamus (P<0.05). Collectively, it was demonstrated that C21 prevented apoptosis and synaptic loss induced by general anesthesia in neonatal rats by enhancing the expression of PPAR-α and Bcl-2.

Introduction

General anesthesia has a great impact on the development of infants and young children (1), and may contribute to the development of learning disabilities (2,3). At the early stage of development, anesthesia and surgery may produce significant cell apoptosis, which reduces hippocampal long-term potentiation (4,5), an important cellular mode of learning and memory (6). A number of anesthetics have been used for the general anesthesia of children. Isoflurane has neuroprotective properties, rapidly induces anesthesia and is metabolized (7,8). Therefore, isoflurane is widely accepted for use in children. However, neurotoxic effects of isoflurane have also been reported. Spatial memory in young and adult animals was impaired following isoflurane anesthesia (9,10). In an animal study, isoflurane administration resulted in the appearance of a large number of apoptotic cells and subsequent cognitive impairment (11). Therefore, it is of clinical significance to identify compounds with the potential to inhibit isoflurane toxicity.

Angiotensin II receptor type 2 (AT2R) is widely expressed in the fetus and in newborns (12). In experimental autoimmune encephalomyelitis models, AT2R is downregulated and an AT2R agonist ameliorates the function of AT2R, which suggests that AT2R is involved in the pathological processes of autoimmune encephalomyelitis (13). Compound (C) 21 is a non-peptide agonist of AT2R, which functions in blood vessel endothelium dilation, inflammatory reaction inhibition and the promotion neuronal repair and regeneration (14-16). However, whether C21 inhibits cell apoptosis caused by isoflurane in neonatal rats has not yet been confirmed.

The BCL2, apoptosis regulator (Bcl-2) is an oncogene which is involved in mitochondria-dependent apoptosis regulation. The expression of Bcl-2 inhibits apoptosis elicited by multiple cytotoxic factors (17,18). In the current study, the protective effects of C21 on isoflurane-induced apoptosis in neonatal rats were investigated, and the underlying mechanisms were assessed. The data revealed that C21 inhibited general anesthesia-induced neuronal apoptosis, likely through promoting Bcl-2 expression.
Materials and methods

Animals and groups. Specific pathogen-free Sprague Dawley rats (n=8; 1:1 male:female; weight, ~252 g) were purchased from Shanghai Super B&K Laboratory Animal Co., Ltd. (license number 2013-0016; Shanghai, China) and maintained in a temperature-controlled environment (25°C) and a humidity of 40-60% with a standard 12 h light/dark cycle and ad libitum access to food and water. All experimental procedures were approved by the ethics committee of Guizhou Medical University (Guiyang, China). A total of 18 pups from four litters were randomly divided into three groups (n=6 in each group; 1:1 male:female): i) Control group, ii) isoflurane group and iii) a C21 treatment group. Postnatal day 7 rats inhaled 1.3% isoflurane (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 3 h each day for a consecutive 3 days. Following the administration of isoflurane, rats in the C21 treatment group received 0.1 ml C21 (1 µg/kg; cat. no. C160; Sigma-Aldrich; Merck KGaA) intraperitoneally each day for a consecutive 4 days, while the rats in the isoflurane group received a similar volume of saline. Rats weighed 10-15 g at the time of sacrifice.

Flow cytometry. The cortex, hippocampus, amygdala and hypothalamus were isolated and ground. A single cell suspension was prepared following trypsinization. A metal mesh was applied to isolate the single cells from the homogenates. Cells were centrifuged at 375 x g for 2 min at 4°C, and 5x10⁶ cells were collected for flow cytometry. Apoptosis was detected using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis kit (cat. no. AP101-100-kit; Hanzhou Multi Sciences (Lianke) Biotech Co., Ltd., Hangzhou, China) according to the manufacturer’s protocol. Following staining with Annexin V-FITC (5 µl) and PI (10 µl) together for 5 min at room temperature, cells were detected using a flow cytometer (NovoCyte 2060R, ACEA Biosciences, Inc., San Diego, CA, USA) with excitation at 488 nm and emission at 530 nm. Data were analyzed using FlowJo 10 (FlowJo LLC, Ashland, OR, USA).

Terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labelling (TUNEL) staining. Collected brain tissues were fixed in 10% formalin at 4°C for 24 h for the TUNEL assay. Cortex, hippocampus, amygdala and hypothalamus were subsequently separated and cryoprotected in 30% sucrose for 1 h at 4°C, prior to slicing into 20 µm sections with a freezing microtome. TUNEL staining (2 µl) was performed using the ApopTag In Situ Apoptosis Detection kit (cat. no. C1089; Beyotime Institute of Biotechnology, Shanghai, China) at 45°C for 2 h, following the manufacturer’s protocol. Following this, 3 drops of mounting medium containing 4',6-diamidino-2-phenylindole (cat. no. ab104139; Abcam, Cambridge, UK) was added and the slides were then covered. After staining, the sections were imaged using fluorescence microscopy (Olympus Corporation, Tokyo, Japan). Four fields in each slice were analyzed and apoptotic cells were counted.

TEM. The bilateral hippocampus was fixed in 2.5% glutaraldehyde at 4°C for 2 h, dehydrated in 70, 75, 80, 85 and 95% ethanol, embedded in paraffin, solidified, and sectioned into 70 nm slices. Following this, sections were stained with 3% uranyl acetate and 3% lead citrate for 7 min at room temperature and imaged using transmission electron microscopy (80 kV; JEM-1230; JEOL, Ltd., Tokyo, Japan).

ELISA. Peroxisome proliferator-activated receptor (PPAR)-α levels were detected with a PPAR-α ELISA kit (cat. no. ml003331; MLbio, Shanghai, China) according to the manufacturer’s protocol. The reagents in the kit were kept at room temperature for 30 min. A standard curve was established. Cortex, hippocampus, hypothalamus and amygdala tissues were homogenized and centrifuged at 11,000 x g for 10 min at 4°C and the supernatants were used in the ELISA. All standard samples and test samples required three duplicates. A blank control, without sample or enzyme reagent, was used. The absorbance was detected at 450 nm using a microplate reader (RT-6100; Rayto Life and Analytical Sciences Co., Ltd., Shenzen, China).

RT-qPCR. mRNA was extracted from rat cortex, hippocampus, hypothalamus and amygdala using a TRIzol® assay kit (Thermo Fisher Scientific, Inc.). The mRNA was transcribed into cDNA using a PrimeScript™ RT-PCR Kit (cat. no. DRR014A; Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer’s protocol (25°C for 9 min, 37°C for 12 min and 85°C for 5 min. SYBR Green
MOLECULAR MEDICINE REPORTS 18: 5337-5344, 2018

5339

(cat. no. HY-K0501; MedChemExpress, Monmouth Junction, NJ, USA) was used to detect the expression level of Bcl-2 using cDNA as a template. qPCR was performed using the following thermocycling conditions: Initial denaturation at 95˚C for 10 min; followed by 36 cycles at 95˚C for 14 sec and 58˚C for 1 min. The 2^ΔΔCq method was used to quantify the results as previously described (19), and relative expression was normalized to GAPDH. The primer sequences are listed in Table I.

Western blot analysis. Homogenates from the cortex, hippocampus, amygdala and hypothalamus were obtained from each group and lysed using an illustra triplePrep Kit (cat. no. 28-9425-44; GE Healthcare Life Sciences). The protein levels were detected using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Protein samples were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with Tris-buffered saline containing 0.1% Tween 20 and 5% fat-free milk for 2 h at room temperature, and were subsequently incubated overnight at 4˚C with rabbit antibodies against Bcl-2 (1:1,500; cat. no. bs-0032R; BIOSS, Beijing, China) and GAPDH (cat. no. A007; 1:1,000; ABelonal Biotech Co., Ltd., Woburn, MA, USA). Following this, membranes were incubated with peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:5,000; cat. no. TA140003; OriGene

Figure 1. TUNEL assay. C21 reduced isoflurane-induced apoptosis in the (A) cortex, (B) hippocampus, (C) hypothalamus and (D) amygdala. Scale bar, 100 µm. TUNEL, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling; C21, compound 21.

Figure 2. Quantification of the terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling assay results. The apoptotic rate of each group was calculated. *P<0.05 vs. control group, #P<0.05 vs. isoflurane group. C21, compound 21.
Technologies, Inc., Beijing, China) for 2 h at room temperature. A chemiluminescent substrate detection reagent (cat. no. RPN2133; GE Healthcare Life Sciences) was applied to assist with staining. The target band was analyzed using Quantity One version 1.4.6 (Bio-Rad Laboratories, Inc.) for densitometric analysis.

Data analysis. The data are expressed as the mean ± standard deviation and were statistically analyzed using SPSS 19 (IBM Corp., Armonk, NY, USA). One-way analysis of variance followed by Newman-Keuls post-hoc test was applied to determine statistical significance. All experiments were repeated six times. P<0.05 was considered to indicate a statistically significant difference.

Results

C21 prevents isoflurane-induced neuronal apoptosis. The TUNEL assay demonstrated that postnatal administration of isoflurane elicited marked apoptosis in the cortex, hippocampus, amygdala and hypothalamus. By contrast, C21 treatment appeared to reduce apoptosis in these four regions.
(Fig. 1). The apoptotic rates in each group were calculated (Fig. 2). In the control groups, the apoptotic rates were 1.23% (cortex), 1.86% (hippocampus), 2.43% (hypothalamus) and 1.40% (amygdala). The apoptotic rates in the isoflurane group were 5.53% (cortex), 5.24% (hippocampus), 5.05% (hypothalamus) and 4.28% (amygdala). The apoptotic rates in the C21+Isoflurane group were 2.87% (cortex), 3.05% (hippocampus), 3.15% (hypothalamus) and 3.29% (amygdala).

Apoptosis was further confirmed by flow cytometry. As shown in Fig. 3, approximately 20% of cells were apoptotic in the isoflurane group, which was significantly reduced by C21 treatment (~8%).

TEM further confirmed that isoflurane induced apoptosis in the hippocampus, which was ameliorated by C21 treatment (Fig. 4). The nuclei of the cells in the control group were round and transparent. The nuclei of the cells in the isoflurane group were shrunken, and condensed chromatin was evident. A marked reduction in synapse numbers was observed in the isoflurane group, but not in the control group. By contrast, the nuclear shrinkage and decrease in synapse number was less prominent in the C21 group.

C21 increases PPAR-α expression. PPAR-α levels in several brain regions were measured using ELISA. As shown in Fig. 5, isoflurane exposure significantly reduced PPAR-α levels in the four selected regions, compared with the control. By contrast, C21 treatment significantly elevated PPAR-α levels compared with the isoflurane group.

C21 increases Bcl-2 expression. Bcl-2 expression in different regions was detected at both the mRNA and protein level. Fig. 6 shows that, isoflurane exposure significantly reduced Bcl-2 mRNA levels in the four selected regions. Additionally, C21 treatment significantly elevated Bcl-2 mRNA expression. Western blot analysis also demonstrated that isoflurane exposure significantly reduced Bcl-2 protein expression in the four selected regions. Furthermore, C21 treatment significantly increased Bcl-2 protein expression.

Discussion

General anesthetics, not only affect the development of neurons, but also damage them (4,5). Previous findings have demonstrated that general anesthetics cause extensive cell death in the brain, reduce the number of brain cells and
decrease synaptic function, resulting in cognitive impairment, and this damage extends to adulthood (20,21). Neonatal rats are the most commonly used model to investigate neurodevelopment (22). The present study investigated the therapeutic effect of C21 on isoflurane-induced apoptosis in neonatal rats. The results revealed that isoflurane exposure caused marked apoptosis in the cortex, hippocampus, amygdala and hypothalamus.

C21 is an AT2R agonist, which has vasodilatory activity, and may protect neuronal function (23). C21-mediated neuroprotection has been widely reported in ischemic injury, vascular dementia and diabetes (24-26). In addition, this neuroprotective effect is likely mediated through an AT2R-dependent pathway or an AT2R-independent pathway (15). In the current study, AT2R expression was not directly measured, in part due to the limitations of available techniques to localize this receptor. However, the neuroprotective activity of C21 in general anesthesia-induced cerebral injury was observed. Synapse number is closely associated with synaptic function, as well as learning and memory (27). TEM analysis revealed that the number of synapses was reduced by isoflurane treatment. C21 treatment increased the number of synapses, which suggested that C21 improved impaired axon and synapse development, which was induced by isoflurane exposure. Neuronal apoptosis is an important component of neurotoxicity (28,29). In immature animal neurons, general anesthesia produces severe cytotoxicity, particularly in synaptic growth (20,21). In the present study, two different methods were utilized to detect apoptosis. A similar trend in each group was observed in the two methods, with C21 treatment attenuating the apoptosis induced by isoflurane. However, the apoptotic rates detected via the two methods were inconsistent, which may have been caused by the different analysis methods utilized in the present study. Flow cytometry may be more effective in determining total apoptosis.

Mitochondrial structure and Bcl-2 family protein expression at the outer membrane destroys mitochondrial permeability transition and mitochondrial pore function. Isoflurane activates the mitochondria-dependent apoptosis pathway and downregulates anti-apoptotic protein B cell lymphoma-extra large expression in the immature brain (30,31). In the current study, TUNEL and flow cytometry were used to detect apoptosis in the cerebral cortex, hippocampus, amygdala and hypothalamus, and apoptosis in the isoflurane group was significantly increased. These results suggested that apoptosis may have been a major cause of the impairment of neurodevelopment following isoflurane exposure. Notably, apoptosis was ameliorated by C21 treatment. These results suggested that C21 had a protective effect against neuronal apoptosis induced by isoflurane. Previous studies have also demonstrated that isoflurane exposure reduces Bcl-2 expression and elicits apoptosis in cerebral tissue (32). Consistent with these findings, the results of the current study also confirmed that the expression of Bcl-2 in the isoflurane groups was significantly decreased. In addition, the present results suggested that C21 protected neonatal rat brain tissue by increasing the expression of Bcl-2.

PPAR-α is a recently discovered target for vascular pathological alterations (33). It is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. When PPAR binds with its ligand, it promotes...
the gene transcription of target cells, and regulates cell cycle, differentiation and apoptosis in various cell types, thereby regulating blood glucose, lipid metabolism and cell differentiation (34). Certain studies have demonstrated that PPAR-α has anti-inflammatory and anti-apoptotic effects (35,36). The results of the current study demonstrated that isoflurane decreased PPAR-α levels in the cerebral cortex, hippocampus, amygdala and hypothalamus. This revealed that isoflurane may have impaired neurodevelopment through PPAR-α expression regulation. Notably, C21 treatment elevated PPAR-α levels in the cerebral cortex, hippocampus, amygdala and hypothalamus. However, the mechanism through which C21 activated PPAR-α still requires further clarification. Based on these data, C21 may be effective in clinically preventing the adverse effects induced by isoflurane anesthesia. However, further studies using animal models as well as clinical studies are required prior to the administration of C21 to children.

In summary, isoflurane damaged the neonatal rat brain by altering the expression of Bcl-2 in the brain, and this was ameliorated by C21 administration. The present study provided a theoretical basis for the safer clinical use of anesthetics.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Science and Technology fund of Guizhou Province (grant no. LH-2015-7394).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

JY, LY, JW and HX performed the experiments and analyzed the data. QZ designed the study and wrote the manuscript.

Ethics approval and consent to participate

All experimental procedures were approved by the ethics committee of Guizhou Medical University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Dong M, Hofacer RD, Jiang C, Joseph B, Hughes EA, Jia B, Danzer SC and Loepeke AW: Brain regional vulnerability to anaesthesia-induced neuroapoptosis shifts with age at exposure and extends into adulthood for some regions. Br J Anaesth 113: 443-451, 2014.

2. Zhang J, Dong Y, Zhou C, Zhang Y and Xie Z: Anesthetic sevoflurane reduces levels of hippocalpin and postsynaptic density protein 95. Mol Neurobiol 51: 853-863, 2015.

3. Zhao T, Li Y, Wei W, Savage S, Zhou L and Ma D: Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring. Neurobiol Dis 68: 145-155, 2014.

4. Cheng Y, He L, Prasad V, Wang S and Levy RJ: Anesthesia-induced neuronal apoptosis in the developing retina: A window of opportunity. Anesth Analg 112: 1375-1335, 2011.

5. Noguchi KK, Johnson SA, Dissen GA, Martin LD, Manzella FM, Schenning KJ, Olney JW and Brambrink AM: Isoflurane exposure for three hour triggers apoptotic cell death in neonatal macaque brain. Br J Anaesth 119: 524-531, 2017.

6. Zhu G, Liu Y, Wang Y, Bi X and Baudry M: Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. J Neurosci 35: 621-633, 2015.

7. Zhao DA, Bi LY, Huang Q, Zhang FM and Han ZM: Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury by suppressing apoptosis. Braz J Anesthesiol 66: 613-621, 2016.

8. Susonov SA, Ameer X, Niatsetskaya ZV, Utkina-Sosunova I, Ratner VI and Ten VS: Isoflurane anesthesia initiated at the onset of reperfusion attenuates oxidative and hypoxic-ischemic brain injury. PLoS One 10: e0120456, 2015.

9. Kalkman CJ, Peelen L, Moons KG, Veeningen MM, Bruns M, Sinnema G and de Jong TP: Behavior and development in children and age at the time of first anesthetic exposure. Anesthesiology 110: 805-812, 2009.

10. Flick RP, Wilder RT, Sprung J, Katzus SK, Voigt R, Colligan R, Schroeder DR, Weaver AL and Warner DO: Anesthesia and cognitive performance in children: No evidence for a causal relationship. Are the conclusions justified by the data? Response to Bartels et al., 2009. Twin Res Hum Genet 12: 611-614, 2009.

11. Li X, Wei K, Hu R, Zhang B, Li L, Wan L, Zhang C and Yao W: Upregulation of Cdh1 attenuates isoflurane-induced neuronal apoptosis and long-term cognitive impairments in developing rats. Front Cell Neurosci 11: 368, 2017.

12. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, Unger T, Bader M, Santos RA, Sumners C and Steckelings UM: Angiotensin type 2 receptor (AT2R) and receptor Mas: A complex liaison. Clin Sci 128: 227-234, 2015.

13. Valero-Esquitino V, Lucht K, Namsolleck P, Monnet-Tschudi F, Stubbbe T, Lucht F, Liu M, Ebner F, Brandt C, Daniell YL, et al.: Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. Clin Sci (Lond) 128: 95-109, 2015.

14. Wang Y, Del Borgo M, Lee HW, Baraldi D, Hirmiz B, Gavapari TA, Denton KM, Aguilar MI, Samuel CS and Widdop RE: Anti-fibrotic potential of AT2 receptor agonists. Front Pharmacol 8: 564, 2017.

15. Bennin DM, Isenberg JD, Harmel AT, DeMars K, Dang AN, Jones CH, Pignataro ME, Graham JT, Steckelings UM, Alexander JC, et al.: Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats. PLoS One 12: e0180738, 2017.

16. Pandey A and Gawkrod AB: Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis. Biochem Biophys Res Commun 487: 827-833, 2017.

17. Um HD: Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: A review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget 7: 5193-5203, 2016.

18. Zheng JH, Vicacva Follis A, Kriwacki RW and Moldoveanu T: Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J 283: 2690-2700, 2016.

19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

20. Wang YL, Chen X and Wang ZP: Detrimental effects of postnatal exposure to propofol on memory and hippocampal LTP in mice. Brain Res 1622: 321-327, 2017.

21. Wang YL, Li F and Chen X: Pten inhibitor-bpV ameliorates early postnatal propofol exposure-induced memory deficit and impairment of hippocampal LTP. Neurochem Res 40: 1593-1599, 2015.
22. Li J, Yang S and Zhu G: Postnatal calpain inhibition elicits cerebellar cell death and motor dysfunction. Oncotarget 8: 87997-88007, 2017.

23. Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA and Allen TJ: AT2R agonist, compound 21, is renoprotective against type 1 diabetic nephropathy. Hypertension 65: 1073-1081, 2015.

24. Iwanami J, Mogi M, Tsukuda K, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ, et al.: Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice. Eur J Pharmacol 724: 9-15, 2014.

25. Min LJ, Mogi M, Tsukuda K, Jing F, Ohshima K, Nakaoka H, Kan-No H, Wang XL, Chisaka T, Bai HY, et al.: Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am J Hypertens 27: 1036-1044, 2014.

26. Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Kan-no H, Chisaka T, Bai HY, Shan BS, Kukida M and Horiuchi M: Direct stimulation of angiotensin II type 2 receptor by compound 21 prevents vascular dementia. J Am Soc Hypertens 9: 250-256, 2015.

27. Zhu G, Wang Y, Li J and Wang J: Chronic treatment with ginsenoside Rg1 promotes memory and hippocampal long-term potentiation in middle-aged mice. Neuroscience 292: 81-89, 2015.

28. Finkel T and Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247, 2000.

29. Zhu G, Wang X, Wu S, Li X and Li Q: Neuroprotective effects of puerarin on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson's disease model in mice. Phytother Res 28: 179-186, 2014.

30. Ozaki M, Deshpande SS, Anglewop K, Bellan J, Lowenstein CJ, Dinauer MC, Goldschmidt-Clermont PJ and Irani K: Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J 14: 418-429, 2000.

31. Lennon SV, Martin SJ and Cotter TG: Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 24: 203-214, 1991.

32. Li W, Li DY, Zhao SM, Zheng ZJ, Hu J, Li ZZ and Xiong SB: Rutin attenuates isoflurane-induced neuroapoptosis via modulating JNK and p38 MAPK pathways in the hippocampi of neonatal rats. Exp Ther Med 13: 2056-2064, 2017.

33. Monsalve FA, Pyarasani RD, Delgado-Lopez F and Moore-Carrasco R: Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013: 549627, 2013.

34. Qian G, Fan W, Ahlemeyer B, Karnati S and Baumgart-Vogt E: Peroxisomes in different skeletal cell types during intramembranous and endochondral ossification and their regulation during osteoblast differentiation by distinct peroxisome proliferator-activated receptors. PLoS One 10: e0143439, 2015.

35. Fong WH, Tsai HD, Chen YC, Wu JS and Lin TN: Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol 41: 180-186, 2010.

36. Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G and Cuzzocrea S: PPAR-α contributes to the anti-inflammatory activity of 17β-estradiol. J Pharmacol Exp Ther 331: 796-807, 2009.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.